- What other names is Dibencozide known by?
- What is Dibencozide?
- How does Dibencozide work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for Dibencozide.
When taken by mouth or placed under the tongue, dibencozide is used to help the body process protein; increase muscle mass and strength; improve mental concentration; and to treat depression, anxiety, and panic attacks.
Insufficient Evidence to Rate Effectiveness for...
- Helping the body process protein.
- Increasing muscle mass and strength.
- Improving mental concentration.
- Panic attacks.
- Other conditions.
Quick GuideVitamin D Deficiency: How Much Vitamin D Is Enough?
Special Precautions & Warnings:Pregnancy and breast-feeding: Not enough is known about the use of dibencozide during pregnancy and breast-feeding. Stay on the safe side and avoid use.
Gastrointestinal (GI) conditions: Some GI conditions, such as ileal disease or surgical removal of part of the intestine, can reduce that amount of Vitamin B12, including dibencozide, that is absorbed from the intestine.
Interaction Rating: Moderate Be cautious with this combination.
Talk with your health provider.
Dibencozide is a form of vitamin B12. Vitamin B12 is important for producing new blood cells. Chloramphenicol might decrease new blood cells. Taking chloramphenicol for a long time might decrease the effects of dibencozide on new blood cells. But most people only take chloramphenicol for a short time so this interaction isn't a big problem.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Last Editorial Review: 3/29/2011